-
Mashup Score: 0FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer - 6 month(s) ago
Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Dostarlimab (Jemperli) approved with chemotherapy for dMMR or MSI-high cancers
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 10FDA Approves Dostarlimab Plus Chemotherapy in MMR/MSI-H Advanced Endometrial Cancer - 8 month(s) ago
FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2FDA to Decide on Dostarlimab Plus Chemo Approval in dMMR/MSI-H Advanced Endometrial Cancer in 4 Months - 10 month(s) ago
According to the developer, a future approval of dostarlimab for this indication would bring the first meaningful frontline treatment for this patient population in decades.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer - 12 month(s) ago
The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer - 1 year(s) ago
New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA's ODAC Supports Proposed Trials for Dostarlimab in dMMR/MSI-H Locally-Advanced Rectal Cancers - 1 year(s) ago
In an 8 to 5 vote, the FDA’s Oncologic Drugs Advisory Committee supported the proposed clinical trial for dostarlimab as treatment of locally advanced, treatment-naïve mismatch-repair deficient or microsatellite-instability-high rectal cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Committee members held reservations about the primary endpoint of clinical CR at 1 year
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of dostarlimab-gxly for a subgroup of patients with rectal cancer, according to the FDA’s Oncologic Drugs Advisory Committee. The panel voted 8-5 that the studies, set to enroll a total of 130 patients, would provide adequate data on use of the anti-PD-1 monoclonal antibody in the
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In this episode of #OncLiveOnAir, Dr Mirza discusses the @US_FDA approval of #dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. #gyncsm https://t.co/tvSDHDkCHx https://t.co/lwpoXzglJ3